Sarepta's stock has plunged due to safety concerns with ELEVIDYS, including two deaths in non-ambulatory DMD patients and regulatory uncertainty. Despite these setbacks, ELEVIDYS remains effective for ambulatory patients, and Sarepta is proactively addressing safety via enhanced immunosuppression and trial amendments. Valuation appears depressed, with the market pricing in a worst-case scenario, but historical precedent (ZOLGENSMA) suggests recovery is possible if risks are managed.

BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND to initiate a Phase 1 clinical study of ORX142 in healthy volunteers. ORX142 is an investigational, novel, highly potent and selective OX2R agonist being developed for the treatment of select neurological and neurodegenerative disorders. ORX142 is the second drug candidate from the Company's multi-asset orexin franchise.

MALVERN, Pa. & TROY, Mich.--(BUSINESS WIRE)--Cantaloupe, Inc. (NASDAQ: CTLP) ("Cantaloupe”), a global technology leader offering end-to-end technology solutions for self-service commerce, today announced it has entered into a definitive agreement to be acquired by 365 Retail Markets, LLC ("365"), a leading innovator in unattended retail technologies, in an all-cash transaction with an equity value of approximately $848 million. 365 is a portfolio company of Providence Equity Partners L.L.C. (“P.

Apple is targeting spring 2026 for the release of its delayed Siri upgrade, as the iPhone maker works to turn around its AI efforts. Bloomberg's Mark Gurman joins Caroline Hyde on “Bloomberg Tech.

It's tempting to go all-in with a massive allocation into the ultra-high-yield QQQI ETF.

Solus' Dan Greenhaus joins 'Closing Bell' to discuss the latest news affecting markets.

Meta has finalized its $14.3 billion investment into Scale AI and plans to hire the company's CEO to join the social media giant's new "superintelligence" team. Bloomberg's Kurt Wagner discusses the deal with Caroline Hyde on “Bloomberg Tech.

@investopedia's Caleb Silver says it's been a "wild year" for inflows, with assets like gold reaching records less than halfway through the year. His firm has measured the investor trends and explains the most interesting points with J.D.

NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your Fortrea Holdings Inc. (NASDAQ:FTRE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fortrea-holdings-inc-lawsuit-submission-form?prid=153064&wire=1&utm_campaign=5 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your PepGen Inc. (NASDAQ:PEPG) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pepgen-inc-lawsuit-submission-form?prid=153065&wire=1&utm_campaign=6 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your Compass Group Diversified Holdings, LLC (NYSE:CODI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/compass-diversified-lawsuit-submission-form?prid=153063&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq.

HOUSTON, TX, June 13, 2025 (GLOBE NEWSWIRE) -- Houston American Energy Corp. (NYSE American: HUSA) (“HUSA” or the “Company”) announced today that the Company had become aware of unusual trading activity in its common stock on the New York Stock Exchange American (the “NYSE”) on June 12 and June 13, 2025. The Company is issuing this press release pursuant to Section 401(d) of the NYSE Company Guide. The Company has made inquiries and has been unable to determine whether corrective actions are appropriate at this time. The Company is further announcing that there has been no material development in its …

Oracle shares popped 24% this week, their best performance since 2001, after the company's earnings report pointed to momentum in its cloud business. The stock has outperformed all of tech's megacaps so far this year.

With the market now full recovered from the tariff-driven selloff, investors should get ready for another double-digit market gain in 2025. Kevin Matras shares his strategy for capitalizing on this powerful rebound.

NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=153059&wire=1&utm_campaign=29 or contact Joseph E.

PASCAGOULA, Miss., June 13, 2025 (GLOBE NEWSWIRE) -- HIl's (NYSE: HII) Ingalls Shipbuilding division honored the 2025 class of master shipbuilders, an elite group of employees who have dedicated 40 years of continuous service to the company, during a special ceremony held at the shipyard June 12. Each of these shipbuilders have committed four decades to building the nation's most advanced naval ships, supporting national security, and mentoring the next generation of shipbuilders.

NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / WHY: New York, N.Y., June 13, 2025.

XPEL is a Buy due to reaccelerating double-digit growth, robust cash flow, and a dominant niche in automotive protection films. The company's asset-light, debt-free model and strong insider ownership support ongoing innovation, acquisitions, and shareholder returns. Premium valuation is justified by high ROE, strong margins, and global expansion opportunities, with analysts seeing 20–50% upside.

High-yield funds are popular passive income machines. However, some are overrated whereas others are underrated by Mr. Market. I discuss one that I think is being overrated by investors and another that is being underrated.

NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.